KOSDAQBiotech & Pharma950130

Access Bio

₩1,647▲ 1.98%2026-11-18 close
Market Cap
₩57.9B
Turnover
₩37,515,936
Volume
20K
Shares out.
35.2M
PER
—
PBR
0.1×
EPS
-₩2,843
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebounds as losses persist at a diagnostics maker

Access Bio's revenue has risen for four straight quarters through the third quarter of 2026, but operating losses have persisted for five, so whether the sales recovery turns into profit is the next checkpoint.

  1. 1

    Annual revenue fell for three consecutive years to KRW 29.3 billion in 2025 (down 73.3% year on year), and quarterly revenue then rose for four straight quarters to KRW 12.7 billion in the third quarter of 2026.

  2. 2

    The operating loss in 2025 was KRW 59.5 billion and the net loss attributable to controlling shareholders was KRW 77.1 billion, while the four quarters from Q4 2025 to Q3 2026 add up to KRW 100 billion in such losses.

  3. 3

    In January 2026 the company took an 80.2% stake in the aesthetics firm RF Bio for KRW 57 billion, and on October 20, 2026 it disclosed a KRW 4.97 billion home-test supply contract with a U.S. subsidiary of P&G.

  4. 4

    Total equity at the end of 2025 was KRW 519.7 billion against total liabilities of KRW 46 billion, but operating cash flow turned negative again at KRW -27.2 billion in 2025.

02

Business structure

Access Bio researches, develops, manufactures and sells rapid diagnostic reagents based on in-vitro diagnostic technology.

Its core product is malaria diagnostics, and the company's profile lists 11 diagnostic products, including RDTs for Plasmodium falciparum and combo tests that detect other malaria species; some products received favorable ratings in WHO quality evaluation reports.

Revenue was built mainly on COVID-19 test kits: in the first half of 2022, COVID-related products accounted for more than 90% of sales, and Oceania made up over 80% by country, according to press reports. A high-sensitivity COVID-19 test kit received full U.S.

FDA approval in February 2025, and the company announced a 2026 push into the U.S. with a combined COVID-19 and influenza test kit.

In January 2026 Access Bio acquired an 80.2% stake in the aesthetics company RF Bio for KRW 57 billion; RF Bio reported 2024 revenue of KRW 20.1 billion and operating profit of KRW 1.7 billion. The same month it invested KRW 15 billion in AAC Holdings and KRW 5 billion in a joint venture called AACG.

The strategy links diagnostics to treatment, aftercare, monitoring and data in a wellness platform. Segment-level revenue shares are not disclosed in the filings reviewed here, but diagnostics remain the core, while aesthetics and wellness are at an early stage.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.4B-₩13.1B−389.6%
2025Q4₩4.7B-₩20.7B−435.9%
2026Q1₩4.9B-₩10.3B−209.6%
2026Q2₩8.6B-₩21.3B−247.9%
2026Q3₩12.7B-₩7.1B−55.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.1T₩485B₩358.3B45.4%55.0%41.4%
2023₩356.6B₩22.1B-₩3.2B6.2%−0.5%17.7%
2024₩110.1B-₩4.1B-₩300M−3.8%−0.1%13.6%
2025₩29.3B-₩59.5B-₩77.1B−202.7%−14.9%8.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, revenue fell from KRW 1.07 trillion in 2022 to KRW 356.6 billion in 2023 (down 66.6% year on year), KRW 110.1 billion in 2024 (down 69.1%) and KRW 29.3 billion in 2025 (down 73.3%).

Revenue declined for three consecutive years from 2023 to 2025; 2022 was the largest year and 2025 the smallest within 2022 to 2025. Press reports say the company attributed the 2025 decline mainly to lower sales as COVID-19 testing demand fell.

Operating profit dropped from KRW 485 billion in 2022 to KRW 22.1 billion in 2023 (down 95.4%), and the company swung to an operating loss of KRW 4.14 billion in 2024. The operating loss widened to KRW 59.5 billion in 2025, the second consecutive loss year.

Operating margin moved from 45.4% in 2022 to 6.2% in 2023, -3.8% in 2024 and -202.7% in 2025, suggesting cost adjustments did not keep pace with the sales decline.

Net profit attributable to controlling shareholders went from KRW 358.3 billion in 2022 to a KRW 3.25 billion loss in 2023, a KRW 340 million loss in 2024 and a KRW 77.1 billion loss in 2025.

Net loss including non-controlling interests was KRW 78 billion in 2025, a different figure from the controlling-shareholder loss.

Quarterly revenue went from KRW 3.36 billion in Q3 2025 to KRW 4.75 billion in Q4 2025 (up 41.2% quarter on quarter), KRW 4.91 billion in Q1 2026 (up 3.5%), KRW 8.58 billion in Q2 2026 (up 74.7%) and KRW 12.7 billion in Q3 2026 (up 47.8%, and up 277.5% year on year), a four-quarter run of increases.

Operating losses over the same period were KRW 13.1 billion, KRW 20.7 billion, KRW 10.3 billion, KRW 21.3 billion and KRW 7.09 billion, which is five straight loss quarters, with the Q3 2026 loss narrower than both the prior quarter and the year-earlier quarter.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 100 billion, and the Q3 2026 figure was KRW 8.27 billion. Operating cash flow was KRW -27.2 billion in 2025, after a KRW 18.1 billion inflow in 2024.

05

Industry analysis

Demand in the company's core market has depended heavily on infectious-disease testing such as COVID-19 and influenza. Press coverage notes that after the pandemic boom ended, growth potential in diagnostics slowed, and that the business relied heavily on public procurement and one-off demand.

In the first half of 2022, the exhaustion of U.S. government testing budgets ended free self-test distribution and reduced sales, according to an analysis at the time. That experience is one reason the company has pushed into non-diagnostic areas.

The P&G subsidiary supply contract disclosed in October 2026 is a test case for whether combined flu and COVID-19 home-test demand in the U.S. can be sustained. The contract amount was calculated on minimum purchase commitments, with no advance payment and payment due within 120 days of invoice receipt.

In aesthetics, the market research firm H&I Global Research has projected that Korea's aesthetic medical market will exceed KRW 1 trillion by 2033, according to press reports. The company is also linked to its largest shareholder group, so group-level business decisions could affect its results.

Within diagnostics, earnings resilience is likely to depend on how concentrated revenue is in a few products and how quickly the company diversifies.

06

Outlook

The next periodic report the company must file is its 2026 annual report, which is due around late March 2027 after the fiscal year ends in December 2026. That filing should show how much RF Bio has added to consolidated results and how fourth-quarter sales developed.

The P&G supply contract runs from October 15, 2026 to October 14, 2027, with a confirmed contract amount of KRW 4,966,068,800, equal to USD 3,728,000 converted at the October 20, 2026 reference rate of KRW 1,332.10 per dollar. The amount is based on minimum purchase commitments, so actual orders may differ.

On the disclosed timing, the contract starts after the third quarter ended, so it does not overlap with Q3 2026 revenue and would first be reflected from Q4 2026 onward.

In wellness, AACG plans to open medical aesthetic clinics in the United States, China and Japan in stages, supplying equipment, injectables and treatment protocols. Press reports from March 2026 quoted the chairman on plans to open med-spa locations in the U.S.

Whether these businesses contribute meaningfully to profit remains to be confirmed in the next annual report. The first-quarter 2027 report is due around mid-May 2027, when investors can check whether the five-quarter run of operating losses ends.

07

Valuation

PER
—
PBR
0.1×
ROE
-19.0%
EPS
-₩2,843
BPS
₩13,661
Dividend per share
₩0

The share price sits well below book net asset value, with the price-to-book ratio far under 1x. Market capitalization is substantially lower than total equity, so the discount to asset value is wide.

Because the company has posted net losses over the last four quarters, a price-to-earnings ratio cannot be calculated, and earnings-based comparisons do not currently apply. The dividend yield is low, so the cash returned to shareholders is limited.

Over several years, results moved from a large profit in 2022 to losses from 2023, and in 2026 the sales recovery has narrowed the losses. Until profit recovery is confirmed, the discount can be read either as a reflection of asset value or as a reflection of the uncertain business transition.

Whether the gap is justified depends on how much of equity is cash and how the acquired assets, including RF Bio, are valued.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Financial capacity and asset base

Total equity at the end of 2025 was KRW 519.7 billion against total liabilities of KRW 46 billion, a debt ratio of 8.9%. Press reports put cash and cash equivalents at about KRW 330 billion as of September 2025. That balance gives the company room to fund its transition and absorb losses.

Quarterly sales recovery

Revenue rose for four straight quarters from Q4 2025 to Q3 2026, and Q3 2026 revenue of KRW 12.7 billion was up 277.5% year on year. The operating loss narrowed to KRW 7.09 billion in Q3 2026 from KRW 21.3 billion in the prior quarter. If the sales recovery carries through, the operating margin has room to improve.

Diversification and overseas supply contract

A supply contract with a P&G subsidiary disclosed on October 20, 2026 has a confirmed amount of KRW 4.97 billion and runs from October 15, 2026 to October 14, 2027. In January 2026 the company acquired 80.2% of RF Bio to broaden its aesthetics product line. Additional revenue streams outside diagnostics could lower reliance on COVID-19 testing demand.

09

Bear factors

Prolonged operating losses

The operating loss in 2025 was KRW 59.5 billion, and the operating margin was -202.7%. Operating losses have continued through each quarter from Q3 2025 to Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 100 billion. Even with a sales recovery, losses could persist if the cost structure does not adjust.

Revenue shrinkage after the pandemic boom

Revenue fell for three consecutive years, to KRW 356.6 billion in 2023, KRW 110.1 billion in 2024 and KRW 29.3 billion in 2025. The 2025 figure is a little under 3% of the KRW 1.07 trillion recorded in 2022. Press coverage points to high reliance on public procurement and one-off demand, which makes results volatile.

Legal disputes and trading history

Press reports from March 2024 said a subsidiary, Access Bio Korea, faced a payment claim of about USD 16.77 million (KRW 22.4 billion) from a consulting firm. A corrected filing related to a damages lawsuit was published in July 2026.

Trading in the shares was suspended in August 2025 after quarterly revenue fell below the listing threshold, and resumed after the exchange removed the stock from its review.

10

Risk factors

Execution of business transition

The company committed KRW 57 billion to RF Bio, KRW 15 billion to AAC Holdings and KRW 5 billion to AACG. Aesthetics and wellness differ from diagnostics and are at an early stage, so the timing of any profit contribution is uncertain. Earnings contribution and any impairment of acquired assets must be checked in the upcoming annual report.

Cash burn and operating cash flow

Operating cash flow swung from KRW 389 billion in 2022 to KRW -107.6 billion in 2023, KRW 18.1 billion in 2024 and KRW -27.2 billion in 2025. Cash on hand is sizable, but continued operating losses would draw it down faster. The more capital goes into acquisitions, the less free cash remains.

Ownership structure and disclosure burden

The largest shareholder group holds about 26.35% of the shares. Following a share cancellation, the listed share count was adjusted to 35,173,834 in May 2026. Repeated lawsuits and corrected filings have drawn attention to disclosure reliability and administrative burden.

11

What to watch next

  1. Around late March 2027

    The 2026 annual report. This filing shows full-year revenue, operating loss, operating cash flow and how much RF Bio contributes after consolidation.

  2. Mid-May 2027

    The Q1 2027 quarterly report. It shows whether the five-quarter run of operating losses narrows further or turns positive.

  3. October 14, 2027

    End of the P&G subsidiary supply contract term. Renewal and actual shipment volumes will indicate whether this revenue is recurring.

12

Overall view

Access Bio's revenue fell from KRW 1.07 trillion in 2022 to KRW 29.3 billion in 2025, then rose for four straight quarters from Q4 2025 through Q3 2026 to KRW 12.7 billion.

Operating losses, however, have continued for five quarters, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 100 billion.

Financially, the company has room, with total equity of KRW 519.7 billion at the end of 2025 and a debt ratio of 8.9%, but operating cash flow turned negative again at KRW -27.2 billion in 2025.

On the business side, the RF Bio acquisition, the AAC Holdings investment and the P&G subsidiary contract read as attempts to build revenue outside diagnostics.

Supporting factors are the quarterly sales recovery and financial capacity; offsetting factors are long-running operating losses, dependence on diagnostic demand and a record of legal disputes.

The next checkpoints are the operating loss in the 2026 annual report and whether the loss streak ends in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.wisereport.co.kr
  2. vegannews.co.kr
  3. thevc.kr
  4. hankyung.com
  5. m.news.nate.com
  6. dailypharm.com
  7. hkn24.com
  8. dailymedi.com
  9. m.thebell.co.kr
  10. specialtimes.co.kr
  11. dailyan.com
  12. accessbio.kr
  13. topstarnews.net
  14. thevc.kr
  15. k5.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis